These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 35403431)

  • 1. Cocktail of REGN Antibodies Binds More Strongly to SARS-CoV-2 Than Its Components, but the Omicron Variant Reduces Its Neutralizing Ability.
    Nguyen H; Lan PD; Nissley DA; O'Brien EP; Li MS
    J Phys Chem B; 2022 Apr; 126(15):2812-2823. PubMed ID: 35403431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies.
    Cao Y; Wang J; Jian F; Xiao T; Song W; Yisimayi A; Huang W; Li Q; Wang P; An R; Wang J; Wang Y; Niu X; Yang S; Liang H; Sun H; Li T; Yu Y; Cui Q; Liu S; Yang X; Du S; Zhang Z; Hao X; Shao F; Jin R; Wang X; Xiao J; Wang Y; Xie XS
    Nature; 2022 Feb; 602(7898):657-663. PubMed ID: 35016194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent antibodies against immune invasive SARS-CoV-2 Omicron subvariants.
    Wang L; Wang Y; Zhou H
    Int J Biol Macromol; 2023 Sep; 249():125997. PubMed ID: 37499711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody cocktail effective against variants of SARS-CoV-2.
    Liang KH; Chiang PY; Ko SH; Chou YC; Lu RM; Lin HT; Chen WY; Lin YL; Tao MH; Jan JT; Wu HC
    J Biomed Sci; 2021 Nov; 28(1):80. PubMed ID: 34814920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omicron: A Heavily Mutated SARS-CoV-2 Variant Exhibits Stronger Binding to ACE2 and Potently Escapes Approved COVID-19 Therapeutic Antibodies.
    Shah M; Woo HG
    Front Immunol; 2021; 12():830527. PubMed ID: 35140714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-nanobody combination increases their neutralizing activity against SARS-CoV-2 and nanobody H11-H4 is effective against Alpha, Kappa and Delta variants.
    Nguyen H; Li MS
    Sci Rep; 2022 Jun; 12(1):9701. PubMed ID: 35690632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies.
    VanBlargan LA; Errico JM; Halfmann PJ; Zost SJ; Crowe JE; Purcell LA; Kawaoka Y; Corti D; Fremont DH; Diamond MS
    Nat Med; 2022 Mar; 28(3):490-495. PubMed ID: 35046573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased neutralization of SARS-CoV-2 global variants by therapeutic anti-spike protein monoclonal antibodies.
    Tada T; Dcosta BM; Zhou H; Vaill A; Kazmierski W; Landau NR
    bioRxiv; 2021 Feb; ():. PubMed ID: 33619484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.
    Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E
    J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies.
    Zhou H; Dcosta BM; Landau NR; Tada T
    Viruses; 2022 Jun; 14(6):. PubMed ID: 35746806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant.
    Schubert M; Bertoglio F; Steinke S; Heine PA; Ynga-Durand MA; Maass H; Sammartino JC; Cassaniti I; Zuo F; Du L; Korn J; Milošević M; Wenzel EV; Krstanović F; Polten S; Pribanić-Matešić M; Brizić I; Baldanti F; Hammarström L; Dübel S; Šustić A; Marcotte H; Strengert M; Protić A; Piralla A; Pan-Hammarström Q; Čičin-Šain L; Hust M
    BMC Med; 2022 Mar; 20(1):102. PubMed ID: 35236358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolation of human monoclonal antibodies with neutralizing activity to a broad spectrum of SARS-CoV-2 viruses including the Omicron variants.
    Ueno M; Iwata-Yoshikawa N; Matsunaga A; Okamura T; Saito S; Ashida S; Yoshida I; Nagashima M; Asakura H; Yaoita Y; Suzuki J; Sadamasu K; Yoshimura K; Kutsuna S; Shiwa-Sudo N; Nagata N; Suzuki T; Suzuki A; Okamoto M; Kimura M; Ohmagari N; Miura R; Ishizaka Y
    Antiviral Res; 2022 May; 201():105297. PubMed ID: 35341809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decoding the effects of spike receptor binding domain mutations on antibody escape abilities of omicron variants.
    Chakraborty S; Saha A; Saha C; Ghosh S; Mondal T
    Biochem Biophys Res Commun; 2022 Oct; 627():168-175. PubMed ID: 36041326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge.
    Shi J; Zheng J; Zhang X; Tai W; Odle AE; Perlman S; Du L
    Transl Res; 2022 Oct; 248():11-21. PubMed ID: 35489692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19.
    Starr TN; Greaney AJ; Addetia A; Hannon WW; Choudhary MC; Dingens AS; Li JZ; Bloom JD
    Science; 2021 Feb; 371(6531):850-854. PubMed ID: 33495308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developing Pseudovirus-Based Neutralization Assay against Omicron-Included SARS-CoV-2 Variants.
    Sun H; Xu J; Zhang G; Han J; Hao M; Chen Z; Fang T; Chi X; Yu C
    Viruses; 2022 Jun; 14(6):. PubMed ID: 35746803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biophysical Fitness Landscape of the SARS-CoV-2 Delta Variant Receptor Binding Domain.
    Patrick C; Upadhyay V; Lucas A; Mallela KMG
    J Mol Biol; 2022 Jul; 434(13):167622. PubMed ID: 35533762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 Omicron Variant Binds to Human Cells More Strongly than the Wild Type: Evidence from Molecular Dynamics Simulation.
    Nguyen HL; Thai NQ; Nguyen PH; Li MS
    J Phys Chem B; 2022 Jun; 126(25):4669-4678. PubMed ID: 35723978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.